Sep 26, 2023
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
Using key discoveries in the field of liver health, we’re advancing treatments for rare and serious liver diseases. Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases.
Primary biliary cholangitis (PBC) is a rare, progressive, and chronic autoimmune disease that causes bile acid to build up in the liver, resulting in inflammation and scarring (fibrosis), which, if left untreated, can lead to cirrhosis, the need for a liver transplant, or death. Therefore, we believe treatment goals should aim to prevent end-stage liver disease and in turn increase transplant-free survival.
Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases.
Clinical trials are a critical part of developing new medicines.
Farnesoid X Receptor (FXR) biology is at the core of our therapeutic research. This treatment modality has applications for PBC and potentially other liver conditions, such as severe alcohol-associated hepatitis.
Since 2002, we’ve pioneered a novel scientific platform to answer critical needs in the liver health community and deliver on our mission to build a healthier tomorrow for people with rare and serious liver diseases.
We’re a dynamic, fast-paced biopharmaceutical company driven by purposeful curiosity and a willingness to do things that haven’t been done before. We recognize that developing new treatments is challenging and that it takes commitment, dedication and deep scientific knowledge, but we are inspired by the opportunity to have a meaningful impact on the lives of patients. As a team, we deliver on our commitment through true collaboration and partnership.
Our company started as a vision in our founder’s small New York City apartment, and we’ve kept that entrepreneurial spirit as we’ve grown to a commercial-stage company more than 300 people strong with a pipeline of innovative and investigational therapies in development.
Our employees are collaborative, passionate and innovative. We embrace our responsibility of pioneering solutions and building hope for patients in need. If you are someone who is self-motivated and sees challenges as opportunities, join us and help us make a difference for those with rare and serious liver diseases.